Evaxion Biotech A/S Files March 2025 6-K Report

Ticker: EVAX · Form: 6-K · Filed: 2025-03-27T00:00:00.000Z

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, regulatory-filing

TL;DR

Evaxion Biotech A/S filed its monthly 6-K report on 3/27/25, standard procedure for foreign issuers.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on March 27, 2025, to report for the month of March 2025. The company is a foreign private issuer based in Hoersholm, Denmark, and is incorporated in G7. Evaxion Biotech A/S is listed under the SIC code 2836 for Biological Products.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Evaxion Biotech A/S's ongoing operations and compliance as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine monthly report for a foreign private issuer and does not contain specific financial or operational news that would indicate a change in risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What period does this Form 6-K cover?

This Form 6-K is for the month of March 2025.

Where is Evaxion Biotech A/S headquartered?

Evaxion Biotech A/S is headquartered in Hoersholm, Denmark.

What is Evaxion Biotech A/S's Standard Industrial Classification (SIC) code?

Evaxion Biotech A/S's SIC code is 2836, which corresponds to Biological Products (no diagnostic substances).

Does Evaxion Biotech A/S file annual reports under Form 20-F?

Yes, Evaxion Biotech A/S indicates with a checkmark that it files or will file annual reports under cover of Form 20-F.

From the Filing

0001171843-25-001763.txt : 20250327 0001171843-25-001763.hdr.sgml : 20250327 20250327081531 ACCESSION NUMBER: 0001171843-25-001763 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250327 FILED AS OF DATE: 20250327 DATE AS OF CHANGE: 20250327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25775424 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_032725.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On March 27, 2025, Evaxion Biotech A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to announce business update and full year 2024 financial results on April 1, 2025". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits Exhibit No.   Description       99.1   Evaxion to announce business update and full year 2024 financial results on April 1, 2025 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

View on Read The Filing